scSTAR reveals hidden heterogeneity with a real-virtual cell pair structure across conditions in single-cell RNA sequencing data

Cell-state transition can reveal additional information from single-cell ribonucleic acid (RNA)-sequencing data in time-resolved biological phenomena. However, most of the current methods are based on the time derivative of the gene expression state, which restricts them to the short-term evolution of cell states. Here, we present single-cell State Transition Across-samples of RNA-seq data (scSTAR), which overcomes this limitation by constructing a paired-cell projection between biological conditions with an arbitrary time span by maximizing the covariance between two feature spaces using partial least square and minimum squared error methods. In mouse ageing data, the response to stress in CD4+ memory T cell subtypes was found to be associated with ageing. A novel Treg subtype characterized by mTORC activation was identified to be associated with antitumour immune suppression, which was confirmed by immunofluorescence microscopy and survival analysis in 11 cancers from The Cancer Genome Atlas Program. On melanoma data, scSTAR improved immunotherapy-response prediction accuracy from 0.8 to 0.96

Integration of Gene Expression and Methylation to unravel Biological Networks in Glioblastoma Patients

peer reviewedThe vast amount of heterogeneous omics data, encompassing a broad range of biomolecular information, requires novel methods of analysis, including those that integrate the available levels of information. In this work we describe Regression2Net, a computational approach that is able to integrate gene expression and genomic or methylome data in two steps. First, penalized regressions are used to build Expression-Expression (EEnet) and Expression-Genome or –Methylome (EMnet) networks. Second, network theory is used to highlight important communities of genes. When applying our approach Regression2Net to gene expression and methylation profiles for individuals with glioblastoma multiforme, we identified respectively 284 and 447 potentially interesting genes in relation to glioblastoma pathology. These genes showed at least one connection in the integrated networks ANDnet and XORnet derived from aforementioned EEnet and EMnet networks. Whereas the edges in ANDnet occur in both EEnet and EMnet, the edges in XORnet occur in EMnet but not in EEnet. In-depth biological analysis of connected genes in ANDnet and XORnet revealed genes that are related to energy metabolism, cell cycle control (AATF), immune system response and several cancer types. Importantly, we observed significant over-representation of cancer related pathways including glioma, especially in the XORnet network, suggesting a non-ignorable role of methylation in glioblastoma multiforma. In the ANDnet, we furthermore identified potential glioma suppressor genes ACCN3 and ACCN4 linked to the NBPF1 neuroblastoma breakpoint family, as well as numerous ABC transporter genes (ABCA1, ABCB1) suggesting drug resistance of glioblastoma tumors

Personalized medicine : the impact on chemistry

An effective strategy for personalized medicine requires a major conceptual change in the development and application of therapeutics. In this article, we argue that further advances in this field should be made with reference to another conceptual shift, that of network pharmacology. We examine the intersection of personalized medicine and network pharmacology to identify strategies for the development of personalized therapies that are fully informed by network pharmacology concepts. This provides a framework for discussion of the impact personalized medicine will have on chemistry in terms of drug discovery, formulation and delivery, the adaptations and changes in ideology required and the contribution chemistry is already making. New ways of conceptualizing chemistry’s relationship with medicine will lead to new approaches to drug discovery and hold promise of delivering safer and more effective therapies

Current challenges in glioblastoma : intratumour heterogeneity, residual disease and models to predict disease recurrence

Glioblastoma (GB) is the most common malignant primary brain tumour, and despite the availability of chemotherapy and radiotherapy to combat the disease, overall survival remains low with a high incidence of tumour recurrence. Technological advances are continually improving our understanding of the disease and in particular our knowledge of clonal evolution, intratumour heterogeneity and possible reservoirs of residual disease. These may inform how we approach clinical treatment and recurrence in GB. Mathematical modelling (including neural networks), and strategies such as multiple-sampling during tumour resection and genetic analysis of circulating cancer cells, may be of great future benefit to help predict the nature of residual disease and resistance to standard and molecular therapies in GB

Robust causal structure learning with some hidden variables

We introduce a new method to estimate the Markov equivalence class of a directed acyclic graph (DAG) in the presence of hidden variables, in settings where the underlying DAG among the observed variables is sparse, and there are a few hidden variables that have a direct effect on many of the observed ones. Building on the so-called low rank plus sparse framework, we suggest a two-stage approach which first removes the effect of the hidden variables, and then estimates the Markov equivalence class of the underlying DAG under the assumption that there are no remaining hidden variables. This approach is consistent in certain high-dimensional regimes and performs favourably when compared to the state of the art, both in terms of graphical structure recovery and total causal effect estimation

Advanced machine learning methods for oncological image analysis

Cancer is a major public health problem, accounting for an estimated 10 million deaths worldwide in 2020 alone. Rapid advances in the field of image acquisition and hardware development over the past three decades have resulted in the development of modern medical imaging modalities that can capture high-resolution anatomical, physiological, functional, and metabolic quantitative information from cancerous organs. Therefore, the applications of medical imaging have become increasingly crucial in the clinical routines of oncology, providing screening, diagnosis, treatment monitoring, and non/minimally- invasive evaluation of disease prognosis. The essential need for medical images, however, has resulted in the acquisition of a tremendous number of imaging scans. Considering the growing role of medical imaging data on one side and the challenges of manually examining such an abundance of data on the other side, the development of computerized tools to automatically or semi-automatically examine the image data has attracted considerable interest. Hence, a variety of machine learning tools have been developed for oncological image analysis, aiming to assist clinicians with repetitive tasks in their workflow. This thesis aims to contribute to the field of oncological image analysis by proposing new ways of quantifying tumor characteristics from medical image data. Specifically, this thesis consists of six studies, the first two of which focus on introducing novel methods for tumor segmentation. The last four studies aim to develop quantitative imaging biomarkers for cancer diagnosis and prognosis. The main objective of Study I is to develop a deep learning pipeline capable of capturing the appearance of lung pathologies, including lung tumors, and integrating this pipeline into the segmentation networks to leverage the segmentation accuracy. The proposed pipeline was tested on several comprehensive datasets, and the numerical quantifications show the superiority of the proposed prior-aware DL framework compared to the state of the art. Study II aims to address a crucial challenge faced by supervised segmentation models: dependency on the large-scale labeled dataset. In this study, an unsupervised segmentation approach is proposed based on the concept of image inpainting to segment lung and head- neck tumors in images from single and multiple modalities. The proposed autoinpainting pipeline shows great potential in synthesizing high-quality tumor-free images and outperforms a family of well-established unsupervised models in terms of segmentation accuracy. Studies III and IV aim to automatically discriminate the benign from the malignant pulmonary nodules by analyzing the low-dose computed tomography (LDCT) scans. In Study III, a dual-pathway deep classification framework is proposed to simultaneously take into account the local intra-nodule heterogeneities and the global contextual information. Study IV seeks to compare the discriminative power of a series of carefully selected conventional radiomics methods, end-to-end Deep Learning (DL) models, and deep features-based radiomics analysis on the same dataset. The numerical analyses show the potential of fusing the learned deep features into radiomic features for boosting the classification power. Study V focuses on the early assessment of lung tumor response to the applied treatments by proposing a novel feature set that can be interpreted physiologically. This feature set was employed to quantify the changes in the tumor characteristics from longitudinal PET-CT scans in order to predict the overall survival status of the patients two years after the last session of treatments. The discriminative power of the introduced imaging biomarkers was compared against the conventional radiomics, and the quantitative evaluations verified the superiority of the proposed feature set. Whereas Study V focuses on a binary survival prediction task, Study VI addresses the prediction of survival rate in patients diagnosed with lung and head-neck cancer by investigating the potential of spherical convolutional neural networks and comparing their performance against other types of features, including radiomics. While comparable results were achieved in intra- dataset analyses, the proposed spherical-based features show more predictive power in inter-dataset analyses. In summary, the six studies incorporate different imaging modalities and a wide range of image processing and machine-learning techniques in the methods developed for the quantitative assessment of tumor characteristics and contribute to the essential procedures of cancer diagnosis and prognosis

GO-2D: identifying 2-dimensional cellular-localized functional modules in Gene Ontology

BACKGROUND: Rapid progress in high-throughput biotechnologies (e.g. microarrays) and exponential accumulation of gene functional knowledge make it promising for systematic understanding of complex human diseases at functional modules level. Based on Gene Ontology, a large number of automatic tools have been developed for the functional analysis and biological interpretation of the high-throughput microarray data. RESULTS: Different from the existing tools such as Onto-Express and FatiGO, we develop a tool named GO-2D for identifying 2-dimensional functional modules based on combined GO categories. For example, it refines biological process categories by sorting their genes into different cellular component categories, and then extracts those combined categories enriched with the interesting genes (e.g., the differentially expressed genes) for identifying the cellular-localized functional modules. Applications of GO-2D to the analyses of two human cancer datasets show that very specific disease-relevant processes can be identified by using cellular location information. CONCLUSION: For studying complex human diseases, GO-2D can extract functionally compact and detailed modules such as the cellular-localized ones, characterizing disease-relevant modules in terms of both biological processes and cellular locations. The application results clearly demonstrate that 2-dimensional approach complementary to current 1-dimensional approach is powerful for finding modules highly relevant to diseases

Biomarker lists stability in genomic studies: analysis and improvement by prior biological knowledge integration into the learning process

The analysis of high-throughput sequencing, microarray and mass spectrometry data has been demonstrated extremely helpful for the identification of those genes and proteins, called biomarkers, helpful for answering to both diagnostic/prognostic and functional questions. In this context, robustness of the results is critical both to understand the biological mechanisms underlying diseases and to gain sufficient reliability for clinical/pharmaceutical applications. Recently, different studies have proved that the lists of identified biomarkers are poorly reproducible, making the validation of biomarkers as robust predictors of a disease a still open issue. The reasons of these differences are referable to both data dimensions (few subjects with respect to the number of features) and heterogeneity of complex diseases, characterized by alterations of multiple regulatory pathways and of the interplay between different genes and the environment. Typically in an experimental design, data to analyze come from different subjects and different phenotypes (e.g. normal and pathological). The most widely used methodologies for the identification of significant genes related to a disease from microarray data are based on computing differential gene expression between different phenotypes by univariate statistical tests. Such approach provides information on the effect of specific genes as independent features, whereas it is now recognized that the interplay among weakly up/down regulated genes, although not significantly differentially expressed, might be extremely important to characterize a disease status. Machine learning algorithms are, in principle, able to identify multivariate nonlinear combinations of features and have thus the possibility to select a more complete set of experimentally relevant features. In this context, supervised classification methods are often used to select biomarkers, and different methods, like discriminant analysis, random forests and support vector machines among others, have been used, especially in cancer studies. Although high accuracy is often achieved in classification approaches, the reproducibility of biomarker lists still remains an open issue, since many possible sets of biological features (i.e. genes or proteins) can be considered equally relevant in terms of prediction, thus it is in principle possible to have a lack of stability even by achieving the best accuracy. This thesis represents a study of several computational aspects related to biomarker discovery in genomic studies: from the classification and feature selection strategies to the type and the reliability of the biological information used, proposing new approaches able to cope with the problem of the reproducibility of biomarker lists. The study has highlighted that, although reasonable and comparable classification accuracy can be achieved by different methods, further developments are necessary to achieve robust biomarker lists stability, because of the high number of features and the high correlation among them. In particular, this thesis proposes two different approaches to improve biomarker lists stability by using prior information related to biological interplay and functional correlation among the analyzed features. Both approaches were able to improve biomarker selection. The first approach, using prior information to divide the application of the method into different subproblems, improves results interpretability and offers an alternative way to assess lists reproducibility. The second, integrating prior information in the kernel function of the learning algorithm, improves lists stability. Finally, the interpretability of results is strongly affected by the quality of the biological information available and the analysis of the heterogeneities performed in the Gene Ontology database has revealed the importance of providing new methods able to verify the reliability of the biological properties which are assigned to a specific feature, discriminating missing or less specific information from possible inconsistencies among the annotations. These aspects will be more and more deepened in the future, as the new sequencing technologies will monitor an increasing number of features and the number of functional annotations from genomic databases will considerably grow in the next years.L’analisi di dati high-throughput basata sull’utilizzo di tecnologie di sequencing, microarray e spettrometria di massa si è dimostrata estremamente utile per l’identificazione di quei geni e proteine, chiamati biomarcatori, utili per rispondere a quesiti sia di tipo diagnostico/prognostico che funzionale. In tale contesto, la stabilità dei risultati è cruciale sia per capire i meccanismi biologici che caratterizzano le malattie sia per ottenere una sufficiente affidabilità per applicazioni in campo clinico/farmaceutico. Recentemente, diversi studi hanno dimostrato che le liste di biomarcatori identificati sono scarsamente riproducibili, rendendo la validazione di tali biomarcatori come indicatori stabili di una malattia un problema ancora aperto. Le ragioni di queste differenze sono imputabili sia alla dimensione dei dataset (pochi soggetti rispetto al numero di variabili) sia all’eterogeneità di malattie complesse, caratterizzate da alterazioni di più pathway di regolazione e delle interazioni tra diversi geni e l’ambiente. Tipicamente in un disegno sperimentale, i dati da analizzare provengono da diversi soggetti e diversi fenotipi (e.g. normali e patologici). Le metodologie maggiormente utilizzate per l’identificazione di geni legati ad una malattia si basano sull’analisi differenziale dell’espressione genica tra i diversi fenotipi usando test statistici univariati. Tale approccio fornisce le informazioni sull’effetto di specifici geni considerati come variabili indipendenti tra loro, mentre è ormai noto che l’interazione tra geni debolmente up/down regolati, sebbene non differenzialmente espressi, potrebbe rivelarsi estremamente importante per caratterizzare lo stato di una malattia. Gli algoritmi di machine learning sono, in linea di principio, capaci di identificare combinazioni non lineari delle variabili e hanno quindi la possibilità di selezionare un insieme più dettagliato di geni che sono sperimentalmente rilevanti. In tale contesto, i metodi di classificazione supervisionata vengono spesso utilizzati per selezionare i biomarcatori, e diversi approcci, quali discriminant analysis, random forests e support vector machines tra altri, sono stati utilizzati, soprattutto in studi oncologici. Sebbene con tali approcci di classificazione si ottenga un alto livello di accuratezza di predizione, la riproducibilità delle liste di biomarcatori rimane ancora una questione aperta, dato che esistono molteplici set di variabili biologiche (i.e. geni o proteine) che possono essere considerati ugualmente rilevanti in termini di predizione. Quindi in teoria è possibile avere un’insufficiente stabilità anche raggiungendo il massimo livello di accuratezza. Questa tesi rappresenta uno studio su diversi aspetti computazionali legati all’identificazione di biomarcatori in genomica: dalle strategie di classificazione e di feature selection adottate alla tipologia e affidabilità dell’informazione biologica utilizzata, proponendo nuovi approcci in grado di affrontare il problema della riproducibilità delle liste di biomarcatori. Tale studio ha evidenziato che sebbene un’accettabile e comparabile accuratezza nella predizione può essere ottenuta attraverso diversi metodi, ulteriori sviluppi sono necessari per raggiungere una robusta stabilità nelle liste di biomarcatori, a causa dell’alto numero di variabili e dell’alto livello di correlazione tra loro. In particolare, questa tesi propone due diversi approcci per migliorare la stabilità delle liste di biomarcatori usando l’informazione a priori legata alle interazioni biologiche e alla correlazione funzionale tra le features analizzate. Entrambi gli approcci sono stati in grado di migliorare la selezione di biomarcatori. Il primo approccio, usando l’informazione a priori per dividere l’applicazione del metodo in diversi sottoproblemi, migliora l’interpretabilità dei risultati e offre un modo alternativo per verificare la riproducibilità delle liste. Il secondo, integrando l’informazione a priori in una funzione kernel dell’algoritmo di learning, migliora la stabilità delle liste. Infine, l’interpretabilità dei risultati è fortemente influenzata dalla qualità dell’informazione biologica disponibile e l’analisi delle eterogeneità delle annotazioni effettuata sul database Gene Ontology rivela l’importanza di fornire nuovi metodi in grado di verificare l’attendibilità delle proprietà biologiche che vengono assegnate ad una specifica variabile, distinguendo la mancanza o la minore specificità di informazione da possibili inconsistenze tra le annotazioni. Questi aspetti verranno sempre più approfonditi in futuro, dato che le nuove tecnologie di sequencing monitoreranno un maggior numero di variabili e il numero di annotazioni funzionali derivanti dai database genomici crescer`a considerevolmente nei prossimi anni

Statistical Methods in Integrative Genomics

Statistical methods in integrative genomics aim to answer important biology questions by jointly analyzing multiple types of genomic data (vertical integration) or aggregating the same type of data across multiple studies (horizontal integration). In this article, we introduce different types of genomic data and data resources, and then review statistical methods of integrative genomics, with emphasis on the motivation and rationale of these methods. We conclude with some summary points and future research directions

Circulating biomarkers predictive of tumor response to cancer immunotherapy

Introduction: The advent of checkpoint blockade immunotherapy has revolutionized cancer treatment, but clinical response to immunotherapies is highly heterogeneous among individual patients and between cancer types. This represents a challenge to oncologists when choosing specific immunotherapies for personalized medicine. Thus, biomarkers that can predict tumor responsiveness to immunotherapies before and during treatment are invaluable. Areas covered: We review the latest advances in 'liquid biopsy' biomarkers for noninvasive prediction and in-treatment monitoring of tumor response to immunotherapy, focusing primarily on melanoma and non-small cell lung cancer. We concentrate on high-quality studies published within the last five years on checkpoint blockade immunotherapies, and highlight significant breakthroughs, identify key areas for improvement, and provide recommendations for how these diagnostic tools can be translated into clinical practice. Expert opinion: The first biomarkers proposed to predict tumor response to immunotherapy were based on PD1/PDL1 expression, but their predictive value is limited to specific cancers or patient populations. Recent advances in single-cell molecular profiling of circulating tumor cells and host cells using next-generation sequencing has dramatically expanded the pool of potentially useful predictive biomarkers. As immunotherapy moves toward personalized medicine, a composite panel of both genomic and proteomic biomarkers will have enormous utility in therapeutic decision-making